Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE LAAC CKD PILOT
2024-516384-93-00Phase 4Authorised
- Sponsor
- National Institute of Cardiology
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of aspirin and clopidogrel in Atrial fibrillation (AFib) and end-stage kidney disease (ESKD) (3 arms), sponsored by National Institute of Cardiology. Primary endpoint: Primary composite endpoint. Planned start Dec 2024; status: authorised.
02
Drugs
aspirinclopidogrel
03
Conditions
Atrial fibrillation (AFib)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2024-516384-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516384-93-00.